The BioHive R.E.P.O.R.T.

Welcome back to the BioHive R.E.P.O.R.T., a bi-weekly rundown of what the Utah Life Sciences community is reading, doing, and saying.

Reading List

Events in the Ecosystem

The BioHive Life Sciences Returnship Workshop Series

September 25th, 2024 @ Kiln / October 7th, 2024 @ Recursion / October 29th, 2024 @ Kiln

BioHive is launching a three-part Returnship Workshop Series to bring together the community of returners, our cohort of host companies, and our partners to advance returnships in the life sciences industry.

What is a Returnship?: A returnship is a temporary, supported role for individuals who have taken an extended absence from their career. Similar to an internship, it can be a highly useful experience for returners to re-enter their field by updating their skills to current industry standards, connecting with peers to rebuild their network, and re-developing confidence in the workspace.

Who is a Returner?: A returner is an individual who has elected to take an extended absence from employment. Several reasons for pausing their career include the following: illness, parental leave, care-giving to family, un-retirement, or military duty.

Please share this opportunity with those in your community who may benefit!

Learn more and RSVP Today

BioUtah Summer BBQ Social

September 19th, 2024, 5:30 PM – 7:00 PM | The Gateway

Save the date and don't miss the annual BioUtah Member BBQ. Meet other life sciences leaders and enjoy R&R BBQ on Thursday, September 19, 2024, from 5:30-7:30 pm. Free for BioUtah members, $25 for non-members.

Learn more and register

Women Tech Council: Women Tech Awards

October 3rd, 2024 | The Grand America

The Women Tech Awards is the leading awards program for women in technology and recognizes some of the most prestigious and up-and-coming women throughout the technology industry. The awards bring visibility to the women who are creating new technologies, leading technology companies, driving innovation and inspiring the tech community.

View the finalists and RSVP

47G Zero Gravity Summit

October 24th, 2024 | The Depot

The Zero Gravity Summit is a global conference on national security and frontier technology that brings together the nation’s leading defense tech founders, venture capital investors, and government leaders.

Experience keynotes, breakouts, and networking focused on the technology that will define our future.

Learn more and register

Programs in the BioHive

BioHive Launches New Student Chapter at Utah Tech University!

On September 11th, we officially launched the BioHive Student Chapter at Utah Tech .

A huge thanks to our chapter leadership, including President Dylan Bistline and VP Karli Nielson, and faculty advisor Doug Sainsbury, for their invaluable support in launching the chapter for the 2024-2025 school year. We were thrilled to host over 50 students at our launch event on the Utah Tech campus, where we highlighted the benefits and opportunities available to students through chapter membership.

Read more about the chapter launch here.

Opportunities

Utah Innovation Center: Funding Opportunities Reminder

A Solicitation of the NIH and CDC for Small Business Innovation Research (SBIR) Contract Proposals

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) are soliciting proposals from small business concerns that possess the research and development (R&D) expertise to conduct innovative research that will contribute toward NIH or CDC mission needs and Small Business Innovation Research (SBIR) program objectives.

Closes October 18th, 2024

Learn more: NIH PHS-2025-1

NSF Small Business Innovation Research / Small Business Technology Transfer Phase I Programs (SBIR/STTR Phase I)

Supports startups and small businesses to transform scientific discovery into products and services with commercial and societal impact. Phase I funding goes to build a proof-of-concept.

Deadline November 6th, 2024

Learn more: NSF ?

Research

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

Recursion's Phase 2 study of REC-994 demonstrated promising trends in MRI-based exploratory efficacy measures at higher doses. The study met its primary endpoint of safety and tolerability, supporting further research and development. Recursion plans to engage with the FDA and continue advancing this potential therapeutic for CCM, a condition with significantly limited treatment options.

View the full press release.

Talk of the Town

Denali Therapeutics to Pursue Accelerated FDA Approval for Hunter Syndrome Treatment

Denali Therapeutics announced a successful meeting with the FDA, setting the stage for the company to file for accelerated approval of Tividenofusp Alfa (DNL310) in early 2025. This treatment targets MPS II (Hunter Syndrome), a rare genetic disorder. Denali will use cerebrospinal fluid heparan sulfate (CSF HS) as a surrogate biomarker to support its application. Interim data from Phase 1/2 trials showed promising results, including reductions in key biomarkers and improvements in clinical outcomes. The accelerated approval would provide faster access to this therapy for patients with significant unmet needs.

View the full press release.

Thanks for reading the R.E.P.O.R.T. We'll see you next time.